stockrowXeris Biopharma Holdings, Inc.
XERS Healthcare Drug Manufacturers Specialty & Generic
Xeris Biopharma Holdings, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $291.8 million, up 43.7% from fiscal 2024.
- Revenue
- +44.2%
- EPS
- +1,479.0%
- Free cash flow
- +93.2%
- Total debt
- −13.6%
Quarter to September 2026, against a year earlier
Follow XERS
Alert me
Xeris Biopharma Holdings, Inc. (XERS) Shares outstanding
Xeris Biopharma Holdings, Inc.'s shares outstanding at the end of fiscal 2025 was $172.7M, up 17.7% from $146.8M in fiscal 2024. At the end of the quarter to 30 September 2026 it was $189.9M. Over the past ten years it has ranged from $1.8M (fiscal 2016) to $172.7M (fiscal 2025) — the current reading is the highest in ten years. Xeris Biopharma Holdings, Inc. ranks 18th of 81 Drug Manufacturers Specialty & Generic companies by shares outstanding.
Shares outstanding, annual
Embed this chart
Annual newest first
| Period | Shares outstanding | Change |
|---|---|---|
| FY2025 | $172.7M | 17.69% |
| FY2024 | $146.8M | 6.61% |
| FY2023 | $137.7M | 1.51% |
| FY2022 | $135.6M | 71.62% |
| FY2021 | $79.0M | 85.32% |
| FY2020 | $42.6M | 63.32% |
| FY2019 | $26.1M | 116.75% |
| FY2018 | $12.0M | 493.98% |
| FY2017 | $2.0M | 10.10% |
| FY2016 | $1.8M | — |
Quarterly newest first
| Period | Shares outstanding | Change |
|---|---|---|
| Sep 2026 | $189.9M | 9.90% |
| Jun 2026 | $172.8M | (2.71%) |
| Mar 2026 | $177.6M | 2.83% |
| Dec 2025 | $172.7M | (2.74%) |
| 33 more quarters | Free account |
Against its own ten years
Shares outstanding against peers
| Company | Shares outstanding |
|---|---|
| ALVO Alvotech compare | $295.0M |
| BCRX BioCryst Pharmaceuticals, Inc. compare | $267.6M |
| HCM HUTCHMED (China) Limited Sponsored ADR compare | $214.3M |
| TRLV Trulieve Cannabis Corp. compare | $200.6M |
| XERS Xeris Biopharma Holdings, Inc. | $189.9M |
| PRGO Perrigo Company plc compare | $139.4M |
| AMLX Amylyx Pharmaceuticals, Inc. compare | $111.2M |
| PBH Prestige Consumer Healthcare Inc. compare | $47.6M |
| RGC Regencell Bioscience Holdings Limited compare | — |
What Shares outstanding is
Shares (Diluted, Weighted) tells an investor how many shares a company’s earnings are spread across once potential new shares are counted.
Reported line item
More on XERS
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement